Long term RZB provides durable efficacy response in PsA through 100 weeks. No new safety signals. Abs 2145 #ACR22 @RheumNow https://t.co/HfJvS1HzDW https://t.co/T67lDnxeLy

• Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Re…

Updated ACR GIOP guidelines: Panel recommends doing Initial fracture risk assessment using the CLINICAL fracture risk assessment then RE-assessing while pts continue on GCs (👇) ☝️Magic nos. GC>/= 2.5mg/d for >3mos #ACR22 @RheumNow @rheumarhyme #Osteoporosis https://t.co/7oWqHg8Tdv

Connolly @CaoilfhionnMD et al. 3 doses SARS-CoV-2 vaccine assoc reduced breakthrough infection in Omicron wave in RMD patients. @RheumNow #ACR22 Abstr#2275 https://t.co/ONXiY8JShK https://t.co/QHNYG9XuJ0

• Three Dose SARS-CoV-2 Vaccination Is Associated with Reduced Risk of Breakthrou…

Wilson et al. Sputum levels of TGF-β1, TNF-α, MCP-1, and IL-4 are significantly elevated in RA-ILD and a portion of these cytokines are also increased in subclinical disease and correlated with lung physiology @RheumNow #ACR22 Abstr#2253 https://t.co/V1fG0QC9od https://t.co/d2YvVIV3Jq

• Sputum Cytokines Are Elevated in Rheumatoid Arthritis-Associated Interstitial L…

Should You Repeat the ENA Panel? Dr. Kathryn Dao ( @KDAO2011) discusses abstract 0725, presented at #ACR22 Convergence. Abstract 0725: Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit https://t.co/6A2ksN6yC2 https://t.co/U62Ab7jj3d

• https://bit.ly/3O9wYMe

Strand et al PROs from SAPHYR (ping @EBRheum ) Significant improvement in SF-36 physical and mental, EQ-5D-3L. Numerical improvement in EQ VAS, FACIT-F, HAQ-DI, PtGA, and pain scores @RheumNow #ACR22 Abstr#2243 https://t.co/RffjBHkjIU https://t.co/0wbnmUhbWy

• Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polym…

"A novel mode of action which has generated a degree of excitement" - Paul Emery PD-1 agonist - peresolimab in RA Good impact in b/tsDMARD refractory patients "Correction of an immune state" - we're shooting for homestasis Definitely a space to watch! ABSTL01 #ACR22 @RheumNow https://t.co/W2lWrBgNOT

McDermott @jeffsparks et al. Subpleural ILAs on CT in 16% RA vs 5% non-RA, OR 3.74. 10 year mortality 53% RA-ILA vs 23% RA non-ILA, 22% non-RA non-ILA. HR mortality 3.20 for RA-ILA vs RA non-ILA @RheumNow #ACR22 Abstr#2248 https://t.co/HZ3y8CANUl https://t.co/nfjFq2REEh

• Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthr…

Figueroa Parra @zach_wallace_md @jeffsparks @AliDuarteMD RA patients have higher risk of severe COVID, especially those with ILD @RheumNow #ACR22 Abstr#2249 https://t.co/xUwStp451C https://t.co/N5A0oo1Kyk

• Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rh…

#ACR22 Abs 2144: JAK inhibition induced different gene profile in circulating immune cells w/prominent downregulation of pro-inflammatory pathways in CD4+naïve T cells AND a shift in their metabolic signaling towards a more quiescent state. @RheumNow https://t.co/qYmr6A3zvS

• JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells …

Dual Energy CT Study in 32 #gout pts on #allopurinol escalated over 2 yrs to achieve Uric acid <6 - tophus urate volumes and tophus soft tissue volumes reduced - chronic inflammatory soft tissue within the tophus is slower to respond than crystals @RheumNow #ACR22 abst#2203 https://t.co/dtHQqg9iFR

BD-2 novel, PsA-specific predictive biomarker of clinical arthritis response to SEC. Pts w/ high levels of BD-2 at baseline reach and sustain higher rates of clinical response after tx w/ SEC. Abs 2148 #ACR22 @RheumNow https://t.co/9ZJz2C0Pep https://t.co/5gf2O7B0c5

• Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Bi…